ClinicalTrials.gg
Not yet recruitingNCT07615738SpO2 PedsUpdated Jul 1, 2026

SpO2 Infant and Pediatric Study

An interventional study of SpO2 Sensor in SpO2 (Peripheral Oxygen Saturation) Measurement Validation and SpO2, sponsored by GE Healthcare. Not yet recruiting at 1 site in United States. Open to participants aged 29 Days to 12 Years. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by GE Healthcare · Not applicable, Interventional, and Device feasibility

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Not applicable
Ages
29 Days to 12 Years
Sex
All
01

Study summary

This study evaluates the pulse oximetry (SpO₂) sensor for clinical performance, form, and fit in hospitalized infants and children (28 days to 12 years). It compares SpO₂ measurements from the device to arterial oxygen saturation (SaO₂) values from arterial CO-oximetry, and assesses the reliability of usable data, performance across skin tones, and user feedback.

Read the detailed description

This prospective clinical study evaluates a pulse oximetry sensor in hospitalized infants (28 days to 23 months) and children (2-12 years) under routine clinical conditions. The primary objective is to assess the accuracy and agreement of SpO₂ measurements compared with reference SaO₂ values obtained from CO-oximetry analysis of simultaneously drawn arterial blood, using methods aligned with ISO 80601-2-61: 2026 3rd edition published in April 2026.

Secondary objectives include measuring the proportion of time the device produces invalid or unusable data to assess reliability for clinical use. The safety objective is to collect safety information, including type and number of AEs, SAEs, and device issues. Results may support product development, regulatory submissions, and marketing activities.

02

Conditions studied

  • SpO2 (Peripheral Oxygen Saturation) Measurement Validation
  • SpO2
03

In context

Lead sponsor

GE Healthcare is the lead sponsor of 176 studies on the registry; 21 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
29 Days to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • subjects are 1-23 months (infant cohort) or 2-12 years old (child cohort)
  • requiring arterial blood samples per the site's standard of care.

Exclusion criteria

Exclusion Criteria:

  • Fractional Methemoglobinemia (FMetHb >2%) or Fractional carboxyhemoglobinemia (FCOHb >3%), within 24 hours of arterial blood draw.
  • Severe anemia (tHb \<7g/dL) within 4 hours prior to arterial blood gas draw.
  • Hematocrit (Hct) \<25 within 4 hours prior to arterial blood gas draw.
  • Patients with injuries, deformities, or abnormalities which may prevent proper application of the sensor.
  • Patients on Extracorporeal Membrane Oxygenation (ECMO).
  • Patients receiving point of care (POC) testing for blood gases.
  • Patients with diseases/conditions that may cause differential (or reverse differential) cyanosis including, but not limited to:
  • Patent ductus arteriosus with pulmonary arterial hypertension.
  • Pulmonary hypertension and left-heart abnormalities aortic arch hypoplasia, interrupted aortic arch, critical coarctation, and critical aortic stenosis.
  • Children with transposition of the great arteries (TGA) and coarctation of the aorta or interrupted aortic arch, and TGA with suprasystemic pulmonary vascular resistance.
  • At the discretion of the principal investigator or designee due to the subject health condition.
05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    All Subjects

    Participants participating in this study will be connected to SpO2 sensors. SpO2 data will be independently collected from each sensor and paired with simultaneous arterial blood sample SaO₂ values. The protocol is consistent with the ISO 80601-2-61 pulse oximetry standard.

    Device: SpO2 Sensor

Interventions

  • DeviceSpO2 Sensor

    SpO2 sensors use red and infrared LED light to estimate the arterial oxygen saturation.

06

What researchers measure

Primary outcomes

  1. Collection of SpO2 Percentage Sensor Data with simultaneous SaO2 values

    The collection of SpO2 percentage sensor data with simultaneous SaO2 values percentage from each subject enrolled in the study.

    Time frame: From enrollment to the end of standard of care arterial cannulation, approximately 1 week.

Other outcomes

  1. Incidence of Safety Events

    Analysis of adverse events will be listed per subject, summarized with counts and percentages of events, and summarized with counts and percentages of subjects with events.

    Time frame: 4 months

07

Study locations

1 site
08

References and documents

Publications

  • Bland JM, Altman DG. Agreement between methods of measurement with multiple observations per individual. J Biopharm Stat. 2007;17(4):571-82. doi: 10.1080/10543400701329422. PubMed 17613642 ↗
  • Ruppel H, Makeneni S, Faerber JA, Lane-Fall MB, Foglia EE, O'Byrne ML, Bonafide CP. Evaluating the Accuracy of Pulse Oximetry in Children According to Race. JAMA Pediatr. 2023 May 1;177(5):540-543. doi: 10.1001/jamapediatrics.2023.0071. PubMed 36939727 ↗
  • Okunlola OE, Lipnick MS, Batchelder PB, Bernstein M, Feiner JR, Bickler PE. Pulse Oximeter Performance, Racial Inequity, and the Work Ahead. Respir Care. 2022 Feb;67(2):252-257. doi: 10.4187/respcare.09795. Epub 2021 Nov 12. PubMed 34772785 ↗
  • Bickler PE, Feiner JR, Severinghaus JW. Effects of skin pigmentation on pulse oximeter accuracy at low saturation. Anesthesiology. 2005 Apr;102(4):715-9. doi: 10.1097/00000542-200504000-00004. PubMed 15791098 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for May 2027, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
May 29, 2026
StartEst.
Jun 15, 2026
Primary completionEst.
May 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07615738
Lead sponsor
GE Healthcare
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Jun 15, 2026 (estimated)
Primary completion
May 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion